171 related articles for article (PubMed ID: 9116271)
1. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.
Engelhard M; Brittinger G; Huhn D; Gerhartz HH; Meusers P; Siegert W; Thiel E; Wilmanns W; Aydemir U; Bierwolf S; Griesser H; Tiemann M; Lennert K
Blood; 1997 Apr; 89(7):2291-7. PubMed ID: 9116271
[TBL] [Abstract][Full Text] [Related]
2. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
Engelhard M; Meusers P; Brittinger G; Brack N; Dornoff W; Enne W; Gassmann W; Gerhartz H; Hallek M; Heise J
Ann Oncol; 1991 Feb; 2 Suppl 2():177-80. PubMed ID: 1710919
[TBL] [Abstract][Full Text] [Related]
3. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification.
Diebold J; Anderson JR; Armitage JO; Connors JM; Maclennan KA; Müller-Hermelink HK; Nathwani BN; Ullrich F; Weisenburger DD
Leuk Lymphoma; 2002 Jan; 43(1):97-104. PubMed ID: 11908742
[TBL] [Abstract][Full Text] [Related]
4. [Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results].
Siegert W; Huhn D; Neubauer A; Brittinger G; Engelhard M; Gerhartz H; Heinz R; Meusers P; Stacher A; Thiel E
Onkologie; 1988 Feb; 11(1):30-4. PubMed ID: 2452392
[TBL] [Abstract][Full Text] [Related]
5. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
O'Reilly SE; Hoskins P; Klimo P; Connors JM
Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
[TBL] [Abstract][Full Text] [Related]
6. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
7. Combined chemotherapy and radiotherapy in diffuse large cell immunoblastic lymphoma: a phase II study of CHOP/bleomycin/methotrexate alternating with ifosfamide/methotrexate/etoposide.
Rodriguez JM; Khan AA
Clin Oncol (R Coll Radiol); 1995; 7(2):113-6. PubMed ID: 7542471
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of primary mediastinal large B-cell lymphomas].
Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
[TBL] [Abstract][Full Text] [Related]
9. [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas].
Krieger G; Kreysing E; Kneba M
Onkologie; 2001 Feb; 24 Suppl 1():49-58. PubMed ID: 11441311
[TBL] [Abstract][Full Text] [Related]
10. German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.
Gerhartz HH; Thiel E; Brittinger G; Dörken B; Engelhard M; Engert W; Enne W; Fuchs R; Hagen-Aukamp CH; Huhn D
Blut; 1988 Mar; 56(3):139-42. PubMed ID: 2451551
[No Abstract] [Full Text] [Related]
11. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
12. [Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
Gerhartz HH; Wilmanns W; Brittinger G; Engelhard M; Heinz R; Huhn D; Meusers P; Siegert W; Stacher A; Thiel E
Onkologie; 1989 Feb; 12(1):22-6. PubMed ID: 2470000
[TBL] [Abstract][Full Text] [Related]
13. Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials.
Bieri S; Roggero E; Zucca E; Bertoni F; Pianca S; Sanna P; Pedrinis E; Bernier J; Cavalli F
Leuk Lymphoma; 1999 Nov; 35(5-6):537-44. PubMed ID: 10609791
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy.
Zinzani PL; Martelli M; Magagnoli M; Zaccaria A; Ronconi F; Cantonetti M; Bocchia M; Marra R; Gobbi M; Falini B; Gherlinzoni F; Moretti L; De Renzo A; Mazza P; Pavone E; Sabattini E; Amendola A; Bendandi M; Pileri SA; Mandelli F; Tura S
Blood; 1998 Aug; 92(3):790-4. PubMed ID: 9680346
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.
Zinzani PL; Bendandi M; Martelli M; Falini B; Sabattini E; Amadori S; Gherlinzoni F; Martelli MF; Mandelli F; Tura S; Pileri SA
J Clin Oncol; 1996 Mar; 14(3):955-62. PubMed ID: 8622045
[TBL] [Abstract][Full Text] [Related]
17. Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.
Heinz R; Hanak H; Stacher A
Klin Wochenschr; 1985 Jul; 63(14):619-26. PubMed ID: 3839867
[TBL] [Abstract][Full Text] [Related]
18. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.
Winter JN; Andersen J; Variakojis D; Gordon LI; Fisher RI; Oken MM; Neiman RS; Jiang S; Bauer KD
Blood; 1996 Nov; 88(10):3919-25. PubMed ID: 8916958
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
